Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...
About 1,000 doses of Gilead Sciences Inc's drug lenacapavir were delivered to Zambia and Eswatini last Thursday, U.S. and ...
Merck said on Wednesday that its experimental oral HIV treatment was not inferior to Gilead's top-selling HIV drug Biktarvy ...
11don MSN
New HIV drug has ‘energised the LGBT community’ according to leading charity in Northern Ireland
A new jab, which will help prevent HIV transmissions, has been described as a ‘game changer’ by an LGBT charity in Northern ...
Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention ...
Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...
Eswatini has become the first African country to receive lenacapavir, a twice-yearly HIV prevention injection that global ...
Merck's HIV pill met key efficacy and safety goals in Phase 3 trials, matching Biktarvy as the FDA reviews its application with a 2026 decision date.
Lenacapavir is an injectable medicine that only needs to be taken twice a year, making it easier to use than daily HIV pills.
The United States has begun distributing a groundbreaking HIV-prevention treatment to two African nations, marking a ...
A new project co-led by Brown researchers is looking to tackle the recent rise in substance abuse, HIV, hepatitis C and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback